The stock of Masco Corporation (NYSE:MAS) was one of the biggest decliners on the NYSE. The company missed expectations for earnings in the first quarter. Masco Corporation (NYSE:MAS) reported earnings of 15 cents a share, which missed analysts’ estimates of 17 cents a share by 2 cents. Masco Corporation (NYSE:MAS) stock performance was -7.44% in…
THT Heat Transfer Technology, Inc. (NASDAQ:THTI), a leading provider of heat exchangers and heat exchange solutions in China’s clean technology industry, announced its financial results for the fourth quarter and fiscal year ended December 31, 2013. Chairman and Chief Executive Officer Guohong Zhao commented, “We are pleased to report the 42% year-over-year revenue growth we…
Ocean Power Technologies, Inc. (Nasdaq:OPTT) announced that Victorian Wave Partners Pty. Ltd. (“VWP”), has received approximately A$5.0 million in initial grant funding from the Australian Renewable Energy Agency (“ARENA”). VWP is a project-specific entity wholly-owned by Ocean Power Technologies (Australasia) Pty. Ltd. (OPTA), which is 88% owned by OPT. Ocean Power Technologies Inc (NASDAQ:OPTT) stock…
Pacific Biosciences of California (NASDAQ:PACB) read length capabilities and accuracy make its systems well-suited for very demanding applications. High-end sequencing company Pacific Biosciences of California (NASDAQ:PACB) still has much left to prove. The company has done a good job of improving system performance and reliability, but the 800lb gorilla in the sequencing space, Illumina (ILMN),…
Pacific Biosciences of California (NASDAQ:PACB) read length capabilities and accuracy make its systems well-suited for very demanding applications. High-end sequencing company Pacific Biosciences of California (NASDAQ:PACB) still has much left to prove. The company has done a good job of improving system performance and reliability, but the 800lb gorilla in the sequencing space, Illumina (ILMN),…
On Oct 20, Sequenta, Inc., announced an equity investment by Celgene Corporation (NASDAQ:CELG) and other strategic investors. This financing, in addition to funding secured from several other strategic investors, will support incorporation of the ClonoSIGHT™ minimal residual disease (MRD) test into clinical trials of medicines in development for various hematological malignancies (blood cancers) and development…
